Description

Iguratimod is a small molecule pharmaceutical compound with significant therapeutic potential. It serves as a selective inhibitor of cyclooxygenase-2 (COX-2), offering a targeted approach to modulating inflammatory pathways. This compound is primarily utilized in pharmaceutical research and development, particularly for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. Its mechanism of action makes it a valuable candidate for advanced drug discovery and clinical studies.

Application

• Active Pharmaceutical Ingredient (API) in the formulation of anti-rheumatic drugs.
• Key intermediate in the synthesis of novel immunomodulatory therapeutics.
• Reference standard for analytical method development and quality control in pharmaceutical laboratories.
• Biochemical research tool for studying COX-2 inhibition and related inflammatory pathways.
• Preclinical and clinical research for autoimmune disease treatment strategies.

Basic Information

Product Name	Iguratimod
CAS No.	123663-50-3
Molecular Formula	C₁₇H₁₄N₂O₂S
Molecular Weight	310.37 g/mol
Synonyms	T-614; 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one; 3-(Formylamino)-7-[(methylsulfonyl)amino]-6-phenoxy-4H-1-benzopyran-4-one; 3-FA-7-MSA-6-phenoxy-4H-1-benzopyran-4-one; Iguratimodum; Iguratimod (USAN)
EINECS	Contact for details

Quality Control

Our Iguratimod is manufactured under strict quality management systems to ensure high purity and batch-to-batch consistency. Each lot undergoes comprehensive analytical testing, including HPLC for assay and related substances, residual solvent analysis, and identification by spectroscopic methods. A Certificate of Analysis (COA) detailing all specifications and test results is provided with every shipment to guarantee compliance with your research and development requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.5%
Related Substances (HPLC)	Total impurities ≤ 1.5% Any single impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH guidelines
Loss on Drying	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.